Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 3/2/2021 (updated 4/5/2024)
Posted 2/3/2021 (updated 4/4/2024)
The opioid epidemic is the result of a complex system of varied and interrelated factors. This webinar introduced a systems thinking approach and tools to address such complex public health challenges. The Georgia Health Policy Center’s Opioid Systems Map was presented as a case study for the creation and application of systems mapping in local communities. The webinar fostered a holistic view of the opioid epidemic and described opportunities to further develop systems thinking capacity for application to grantees’ local opioid response.
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 2/4/2020 (updated 3/28/2024)
A Systems Perspective of the Opioid Epidemic Webinar Presentation and Materials
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).